

Halaven Approval Status Worldwide (Country/ Region)

April, 2021

Breast Cancer 3rd line

Algeria	May-2019	Estonia	Mar-2011	Lithuania	Mar-2011	Saudi Arabia	Nov-2014
Argentina	Jun-2019	Finland	Mar-2011	Luxembourg	Mar-2011	Serbia	Aug-2013
Australia	Aug-2012	France	Mar-2011	Macau	Jun-2012	Singapore	Feb-2011
Austria	Mar-2011	Germany	Mar-2011	Malaysia	Sep-2012	Slovakia	Mar-2011
Bahrain	Jun-2016	Greece	Mar-2011	Malta	Mar-2011	Slovenia	Mar-2011
Belgium	Mar-2011	Hong Kong	Dec-2012	Mexico	Aug-2014	South Africa	Jul-2016
Bosnia and Herzegovina	Jul-2013	Hungary	Mar-2011	Morocco	Dec-2014	South Korea	Aug-2012
Brazil	May-2013	Iceland	Mar-2011	Myanmar	Dec-2013	Spain	Mar-2011
Brunei	Dec-2018	India	Apr-2013	Netherlands	Mar-2011	Sri Lanka	Jan-2019
Bulgaria	Mar-2011	Indonesia	Dec-2015	Norway	Mar-2011	Sweden	Mar-2011
Cambodia	Oct-2017	Ireland	Mar-2011	Oman	Nov-2016	Switzerland	May-2011
Canada	Dec-2011	Israel	May-2012	Pakistan	Jan-2019	Taiwan	Aug-2013
China	Jul-2019	Italy	Mar-2011	Panama	May-2020	Thailand	Dec-2012
Chile	Sep-2019	Japan	Apr-2011	Peru	Jun-2019	UAE	Jan-2015
Croatia	Jun-2012	Jordan	May-2014	Philippines	Mar-2013	UK	Mar-2011
Cyprus	Mar-2011	Kuwait	Oct-2012	Poland	Mar-2011	US	Nov-2010
Czech Republic	Mar-2011	Laos	Sep-2013	Portugal	Mar-2011	Vietnam	Jul-2019
Denmark	Mar-2011	Latvia	Mar-2011	Qatar	Aug-2017		
Ecuador	Aug-2020	Lebanon	May-2013	Romania	Mar-2011		
Egypt	Dec-2019	Liechtenstein	Mar-2011	Russia	Jul-2012		

Note: The purpose of this document is to demonstrate that Eisai seeks to expand access to its products for patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.

Halaven Approval Status Worldwide (Country/ Region)

April, 2021

Breast Cancer, 2nd line

Argentina	Jun-2019	Germany	Jun-2014	Morocco	Dec-2014	Spain	Jun-2014
Australia	Nov-2015	Greece	Jun-2014	Myanmar	Oct-2015	Sri Lanka	Jan-2019
Austria	Jun-2014	Hong Kong	Oct-2014	Namibia	Aug-2018	Sweden	Jun-2014
Bahrain	Nov-2019	Hungary	Jun-2014	Netherlands	Jun-2014	Switzerland	Jul-2014
Bangladesh	Jul-2019	Iceland	Jun-2014	Norway	Jun-2014	Thailand	Aug-2014
Belgium	Jun-2014	India	Feb-2015	Oman	Sep-2020	UAE	Nov-2018
Bosnia and Herzegovina	Sep-2015	Ireland	Jun-2014	Pakistan	Jan-2019	UK	Jun-2014
Brazil	Sep-2018	Israel	Nov-2014	Panama	May-2020	Vietnam	Jul-2019
Bulgaria	Jun-2014	Italy	Jun-2014	Peru	Jun-2019	Zambia	Feb-2021
Cambodia	Oct-2017	Jordan	Oct-2020	Philippines	Sep-2014	Zimbabwe	Jan-2021
Chile	Sep-2019	Kuwait	Sep-2018	Poland	Jun-2014		
Croatia	Jun-2014	Latvia	Jun-2014	Portugal	Jun-2014		
Cyprus	Jun-2014	Lebanon	Feb-2018	Romania	Jun-2014		
Czech Republic	Jun-2014	Liechtenstein	Jun-2014	Russia	Nov-2014		
Denmark	Jun-2014	Lithuania	Jun-2014	Saudi Arabia	Jan-2019		
Ecuador	Aug-2020	Luxembourg	Jun-2014	Serbia	Feb-2018		
Egypt	Dec-2019	Macau	Apr-2015	Slovakia	Jun-2014		
Estonia	Jun-2014	Malaysia	May-2018	Slovenia	Jun-2014		
Finland	Jun-2014	Malta	Jun-2014	South Africa	May-2019		
France	Jun-2014	Mexico	Mar-2018	South Korea	Dec-2014		

In Japan, Halaven® is approved for the treatment of inoperable and recurrent breast cancer.

Note: The purpose of this document is to demonstrate that Eisai seeks to expand access to its products for patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.

Halaven Approval Status Worldwide (Country/ Region)

April, 2021

Soft Tissue Sarcoma

Argentina	Jun-2019	France	May-2016	Malaysia	May-2018	Slovakia	May-2016
Australia	Nov-2016	Germany	May-2016	Malta	May-2016	Slovenia	May-2016
Austria	May-2016	Greece	May-2016	Mexico	Mar-2018	South Africa	May-2019
Bahrain	Nov-2019	Hong Kong	Feb-2017	Morocco	May-2018	South Korea	Jan-2017
Bangladesh	Jul-2019	Hungary	May-2016	Myanmar	Oct-2018	Spain	May-2016
Belgium	May-2016	Iceland	May-2016	Namibia	Aug-2018	Sri Lanka	Jan-2019
Bosnia and Herzegovina	Feb-2018	India	Oct-2016	Netherlands	May-2016	Sweden	May-2016
Brazil	Sep-2018	Indonesia	Jun-2018	Norway	May-2016	Switzerland	Dec-2016
Bulgaria	May-2016	Ireland	May-2016	Oman	Sep-2020	Taiwan	Nov-2016
Cambodia	Mar-2020	Israel	Oct-2016	Pakistan	Jan-2019	Thailand	Sep-2017
Canada	Aug-2017	Italy	May-2016	Panama	May-2020	UAE	Nov-2018
Chile	Sep-2019	Japan	Feb-2016	Peru	Jun-2019	US	Jan-2016
Croatia	May-2016	Jordan	Oct-2020	Philippines	May-2016	UK	May-2016
Cyprus	May-2016	Kuwait	Sep-2018	Poland	May-2016	Zambia	Feb-2021
Czech Republic	May-2016	Latvia	May-2016	Portugal	May-2016	Zimbabwe	Jan-2021
Denmark	May-2016	Lebanon	Feb-2018	Romania	May-2016		
Ecuador	Aug-2020	Liechtenstein	May-2016	Russia	Jun-2016		
Egypt	Dec-2019	Lithuania	May-2016	Saudi Arabia	Jan-2019		
Estonia	May-2016	Luxembourg	May-2016	Serbia	Apr-2019		
Finland	May-2016	Macau	Jun-2017	Singapore	Mar-2017		

Note: The purpose of this document is to demonstrate that Eisai seeks to expand access to its products for patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.